Principal Financial Group Inc. Has $4.10 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Principal Financial Group Inc. raised its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 14.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 430,558 shares of the biotechnology company’s stock after acquiring an additional 53,990 shares during the period. Principal Financial Group Inc. owned about 0.17% of BioCryst Pharmaceuticals worth $4,099,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of BCRX. Candriam S.C.A. acquired a new stake in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $21,771,000. Hsbc Holdings PLC boosted its holdings in BioCryst Pharmaceuticals by 30.5% during the first quarter. Hsbc Holdings PLC now owns 31,499 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 7,366 shares during the last quarter. Kestra Advisory Services LLC boosted its holdings in BioCryst Pharmaceuticals by 20.5% during the first quarter. Kestra Advisory Services LLC now owns 15,740 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 2,680 shares during the last quarter. Capricorn Fund Managers Ltd bought a new position in BioCryst Pharmaceuticals in the first quarter valued at $1,932,000. Finally, Janney Montgomery Scott LLC grew its position in BioCryst Pharmaceuticals by 524.8% in the first quarter. Janney Montgomery Scott LLC now owns 163,266 shares of the biotechnology company’s stock valued at $1,554,000 after purchasing an additional 137,133 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

BCRX has been the topic of several recent research reports. Needham & Company LLC lowered their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Cantor Fitzgerald raised their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Royal Bank Of Canada raised their price objective on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Citizens Jmp lifted their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. began coverage on BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.80.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $9.74 on Wednesday. The firm’s 50-day moving average is $9.25 and its 200-day moving average is $8.60. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -5.47 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a 52-week low of $6.00 and a 52-week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. During the same quarter last year, the business posted $0.20 earnings per share. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.58 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.